Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
cholangioblastic variant of intrahepatic cholangiocarcinoma in a young adult with situs inversus totalis
Original title: “Cholangioblastic variant of intrahepatic cholangiocarcinoma in a young adult with situs inversus totalis.”
chronic liver disease is associated with earlier stage cholangiocarcinoma diagnosis and improved prognosis findings from the global btc registry
Original title: “Chronic liver disease is associated with earlier-stage cholangiocarcinoma diagnosis and improved prognosis: Findings from the GLOBAL-BTC registry.”
cholangiocarcinoma in a 33 year old male with cd40l deficiency and pre papillary bile duct stenosis
Original title: “Cholangiocarcinoma in a 33-year-old male with CD40L deficiency and pre-papillary bile duct stenosis.”
machine learning for population level risk prediction of future cholangiocarcinoma
Original title: “Machine learning for population-level risk prediction of future cholangiocarcinoma.”
case of chronic cholangitis caused by calculi with foreign matter mimicking perihilar cholangiocarcinoma
Original title: “A case of chronic cholangitis caused by calculi with foreign matter mimicking perihilar cholangiocarcinoma.”
from infection to cholangiocarcinoma why opisthorchiids break these rules
Original title: “From infection to cholangiocarcinoma: Why opisthorchiids break these rules.”
tert rs10069690 variant is linked to reduced cholangiocarcinoma incidence but adverse prognosis in patients undergoing resection
Original title: “TERT rs10069690 variant is linked to reduced cholangiocarcinoma incidence but adverse prognosis in patients undergoing resection.”
hepatocellular carcinoma cholangiocarcinoma collision tumor with excellent therapeutic response a case report and literature review
Original title: “Hepatocellular carcinoma-cholangiocarcinoma collision tumor with excellent therapeutic response: a case report and literature review.”
FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.
Original title: “FDA Grants Seventh Approval under the National Priority Voucher Pilot Program”
end of life care patterns for cholangiocarcinoma in the united states a 26 year analysis of home and hospice deaths by demographic regional and urbanization factors
Original title: “End-of-Life Care Patterns for Cholangiocarcinoma in the United States: A 26-Year Analysis of Home and Hospice Deaths by Demographic, Regional, and Urbanization Factors.”
molecular profiling of cholangiocarcinoma predicts outcomes post liver transplantation
Original title: “Molecular Profiling of Cholangiocarcinoma Predicts Outcomes Post-Liver Transplantation.”
successful management of suspected epstein barr virus associated hemophagocytic lymphohistiocytosis in braf mutant cholangiocarcinoma following treatment with immune checkpoint inhibitors and braf mek inhibitors a case report
Original title: “Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report.”
fibroblast growth factor receptor fgfr inhibitors for the treatment of cholangiocarcinoma key therapeutic developments and knowledge gaps
Original title: “Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps.”
phase i results of a multicenter open label dose de escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma
Original title: “Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma.”